Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (DE:J7Z)
:J7Z
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
4.61Last Year’s EPS
2.56Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 3.92%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record revenues, successful product launches, and strong sales growth for key products like Epidiolex. However, challenges such as the impact of pediatric protocol changes on Rylaze and potential revenue erosion from upcoming generic competition were noted. The company demonstrated financial strength by reducing debt and maintaining strategic flexibility.Company Guidance
In the recent earnings call, Jazz Pharmaceuticals provided comprehensive guidance for 2025, highlighting several key metrics. The company reported total revenues of approximately $4.1 billion for 2024, marking a 6% increase over 2023, and expects 2025 revenues to range between $4.15 billion and $4.4 billion. They achieved a non-GAAP adjusted net income of about $1.37 billion in 2024, with an adjusted EPS of $20.90. Jazz anticipates continued growth in 2025, driven by strong performance in their sleep, epilepsy, and oncology portfolios, with Xywav and Epidiolex poised to drive significant revenue. The company also highlighted a reduction in non-GAAP adjusted R&D expenses by 8% from 2024, focusing on priority programs like zanidatamab. Additionally, they expect adjusted net income for 2025 to range from $1.4 billion to $1.5 billion, reflecting their strategic investments and disciplined expense management.Record Annual and Quarterly Revenue
Jazz Pharmaceuticals reported over $4 billion in total annual revenue for 2024 and nearly $1.1 billion in fourth quarter revenue, marking the highest ever quarterly revenue.
Strong Growth in Epidiolex Sales
Epidiolex net product revenues grew 15% in 2024 compared to 2023, showing strong underlying demand and positioning the product to reach blockbuster status in 2025.
Successful Launch of Ziihera
Ziihera received accelerated approval in the U.S. for HER2-positive biliary tract cancer and generated positive initial feedback from healthcare providers.
Zepzelca Phase III Clinical Success
Positive results from the Phase III trial for Zepzelca in first-line maintenance for small cell lung cancer, indicating potential for expanded use.
Financial Flexibility and Debt Reduction
Significant cash generation allowed for a $750 million voluntary repayment on Term Loan B, reducing leverage substantially.
---
DE:J7Z Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:J7Z Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | €132.50 | €137.75 | +3.96% |
| Nov 06, 2024 | €103.50 | €110.15 | +6.43% |
| Jul 31, 2024 | €101.75 | €106.10 | +4.28% |
| Feb 28, 2024 | €121.15 | €110.05 | -9.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Jazz Pharmaceuticals (DE:J7Z) report earnings?
Jazz Pharmaceuticals (DE:J7Z) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Jazz Pharmaceuticals (DE:J7Z) earnings time?
Jazz Pharmaceuticals (DE:J7Z) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Jazz Pharmaceuticals stock?
The P/E ratio of Jazz Pharmaceuticals is N/A.
What is DE:J7Z EPS forecast?
DE:J7Z EPS forecast for the fiscal quarter 2025 (Q1) is 4.61.
---